Welcome to NewsHome

This website is intended for journalists or healthcare professionals outside the US/UK who are interested in media information from Boehringer Ingelheim. Please choose an option below:

I am a journalist or HCP outside the US/UKI am a journalist or HCP in the US/UKI am not a journalist or HCP
 
LUX Lung 1 clinical trial thumb
 
Rating:00
view image larger
Related links:
Lung cancer backgrounder Thumbnail
Lung Cancer Backgrounder
Read more >
ErbB Family Blockade Infographic thumb
ErbB family Blockade and Afatinib Infographic
Read more >

LUX Lung 1 clinical trial fact sheet

01.05.2011

LUX-Lung 1 is a clinical Phase IIb/III randomised, double-blind study evaluating afatinib* in combination with best supportive care (BSC) versus placebo plus BSC in patients with advanced non-small-cell lung cancer (NSCLC). Patients' disease has progressed after prior chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) gefitinib or erlotinib treatment. Due to the study inclusion criteria a high proportion of patients that may have mutated EGF receptors in their tumours were included.
1. Miller et al. Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1). Oral presentation at the 35th European Society of Medical Oncology (ESMO) annual meeting, Milan, October 2010. Abstract ID: LBA1.
VIEW PREVIEW ADD TO SELECTION DOWNLOAD